Overview

Single Ascending Dose Study of PRX002 in Healthy Subjects

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Prothena Biosciences Limited
Collaborator:
Hoffmann-La Roche